Development
e-therapeutics plc
ETXPF
OTC PK
| 07/31/2023 | 04/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 3.68% | -9.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.68% | -9.95% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 3.68% | -9.95% | |||
| SG&A Expenses | 3.66% | 3.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.66% | 23.19% | |||
| Operating Income | -3.66% | -24.24% | |||
| Income Before Tax | -3.66% | -27.95% | |||
| Income Tax Expenses | -3.66% | -33.17% | |||
| Earnings from Continuing Operations | -3.66% | -27.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.66% | -27.03% | |||
| EBIT | -3.66% | -24.24% | |||
| EBITDA | -3.66% | -20.12% | |||
| EPS Basic | -3.39% | -22.92% | |||
| Normalized Basic EPS | -4.55% | -25.71% | |||
| EPS Diluted | -3.39% | -22.92% | |||
| Normalized Diluted EPS | -4.55% | -25.71% | |||
| Average Basic Shares Outstanding | 0.00% | 3.06% | |||
| Average Diluted Shares Outstanding | 0.00% | 3.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||